Injectual Ltd 13496830 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is that of medical procedures. Digita Accounts Production Advanced 6.30.9574.0 true true 13496830 2024-01-01 2024-12-31 13496830 2024-12-31 13496830 bus:OrdinaryShareClass1 2024-12-31 13496830 core:HirePurchaseContracts core:CurrentFinancialInstruments 2024-12-31 13496830 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2024-12-31 13496830 core:CurrentFinancialInstruments 2024-12-31 13496830 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 13496830 core:Non-currentFinancialInstruments core:AfterOneYear 2024-12-31 13496830 core:OtherResidualIntangibleAssets 2024-12-31 13496830 core:FurnitureFittings 2024-12-31 13496830 core:LandBuildings core:ShortLeaseholdAssets 2024-12-31 13496830 core:PlantMachinery 2024-12-31 13496830 bus:SmallEntities 2024-01-01 2024-12-31 13496830 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 13496830 bus:FilletedAccounts 2024-01-01 2024-12-31 13496830 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13496830 bus:RegisteredOffice 2024-01-01 2024-12-31 13496830 bus:Director1 2024-01-01 2024-12-31 13496830 bus:Director2 2024-01-01 2024-12-31 13496830 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 13496830 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13496830 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-01-01 2024-12-31 13496830 core:IntangibleAssetsOtherThanGoodwill 2024-01-01 2024-12-31 13496830 core:OtherResidualIntangibleAssets 2024-01-01 2024-12-31 13496830 core:FurnitureFittings 2024-01-01 2024-12-31 13496830 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 13496830 core:LandBuildings core:ShortLeaseholdAssets 2024-01-01 2024-12-31 13496830 core:PlantMachinery 2024-01-01 2024-12-31 13496830 countries:AllCountries 2024-01-01 2024-12-31 13496830 2023-12-31 13496830 core:OtherResidualIntangibleAssets 2023-12-31 13496830 core:FurnitureFittings 2023-12-31 13496830 core:LandBuildings core:ShortLeaseholdAssets 2023-12-31 13496830 core:PlantMachinery 2023-12-31 13496830 2023-01-01 2023-12-31 13496830 2023-12-31 13496830 bus:OrdinaryShareClass1 2023-12-31 13496830 core:HirePurchaseContracts core:CurrentFinancialInstruments 2023-12-31 13496830 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2023-12-31 13496830 core:CurrentFinancialInstruments 2023-12-31 13496830 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 13496830 core:Non-currentFinancialInstruments core:AfterOneYear 2023-12-31 13496830 core:OtherResidualIntangibleAssets 2023-12-31 13496830 core:FurnitureFittings 2023-12-31 13496830 core:LandBuildings core:ShortLeaseholdAssets 2023-12-31 13496830 core:PlantMachinery 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13496830

Injectual Ltd

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2024

 

Injectual Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 10

 

Injectual Ltd

Company Information

Directors

Dr Veerle Karine Rotsaert

Miss Joelle Rotsaert

Registered office

59 Westbourne Grove
Westbourne Green
London
W2 4UA

Accountants

Thorntons Accounting Limited
Chartered Certified Accountants
176-178 Pontefract Road
Cudworth
Barnsley
South Yorkshire
S72 8BE

 

Injectual Ltd

(Registration number: 13496830)
Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Intangible assets

4

76,215

82,924

Tangible assets

5

371,481

186,948

 

447,696

269,872

Current assets

 

Stocks

6

80,000

40,000

Debtors

7

63,956

42,731

Cash at bank and in hand

 

6,277

28,497

 

150,233

111,228

Creditors: Amounts falling due within one year

8

(633,243)

(503,269)

Net current liabilities

 

(483,010)

(392,041)

Total assets less current liabilities

 

(35,314)

(122,169)

Creditors: Amounts falling due after more than one year

8

(442)

(3,088)

Net liabilities

 

(35,756)

(125,257)

Capital and reserves

 

Called up share capital

9

100

100

Retained earnings

(35,856)

(125,357)

Shareholders' deficit

 

(35,756)

(125,257)

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

 

Injectual Ltd

(Registration number: 13496830)
Balance Sheet as at 31 December 2024

Approved and authorised by the Board on 2 April 2025 and signed on its behalf by:
 

.........................................
Dr Veerle Karine Rotsaert
Director

 

Injectual Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
59 Westbourne Grove
Westbourne Green
London
W2 4UA

These financial statements were authorised for issue by the Board on 2 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

Injectual Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

10% straight line

Fixtures & Fittings

20% straight line

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Other Intangible

Over 16 years

Leasehold improvements

Over 16 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

 

Injectual Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the profit and loss account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 5 (2023 - 4).

 

Injectual Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

4

Intangible assets

Other intangible assets
 £

Total
£

Cost or valuation

At 1 January 2024

96,342

96,342

At 31 December 2024

96,342

96,342

Amortisation

At 1 January 2024

13,418

13,418

Amortisation charge

6,709

6,709

At 31 December 2024

20,127

20,127

Carrying amount

At 31 December 2024

76,215

76,215

At 31 December 2023

82,924

82,924

5

Tangible assets

Short leasehold land and buildings
£

Fixtures and fittings
£

Plant and machinery
£

Total
£

Cost or valuation

At 1 January 2024

194,254

8,289

12,982

215,525

Additions

120,500

86,882

7,619

215,001

At 31 December 2024

314,754

95,171

20,601

430,526

Depreciation

At 1 January 2024

22,721

3,260

2,596

28,577

Charge for the year

20,818

7,564

2,086

30,468

At 31 December 2024

43,539

10,824

4,682

59,045

Carrying amount

At 31 December 2024

271,215

84,347

15,919

371,481

At 31 December 2023

171,533

5,029

10,386

186,948

 

Injectual Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Included within the net book value of land and buildings above is £271,215 (2023 - £171,533) in respect of short leasehold land and buildings.
 

6

Stocks

2024
£

2023
£

Other inventories

80,000

40,000

7

Debtors

2024
£

2023
£

Other debtors

45,623

42,731

Prepayments

18,333

-

63,956

42,731

 

Injectual Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

8

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Loans and borrowings

10

158,475

46,246

Taxation and social security

 

3,621

1,846

Accruals and deferred income

 

13,521

5,065

Other creditors

 

457,626

450,112

 

633,243

503,269

Creditors: amounts falling due after more than one year

Note

2024
£

2023
£

Due after one year

 

Loans and borrowings

10

442

3,088

9

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary of £1 each

100

100

100

100

       

10

Loans and borrowings

Non-current loans and borrowings

2024
£

2023
£

Hire purchase contracts

442

3,088

Current loans and borrowings

2024
£

2023
£

Hire purchase contracts

2,646

2,646

Other borrowings

155,829

43,600

158,475

46,246

 

Injectual Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

11

Related party transactions

Directors' remuneration

The directors' remuneration for the year was as follows:

2024
£

2023
£

Remuneration

30,742

9,680

Contributions paid to money purchase schemes

700

227

31,442

9,907